v3.26.1
Insider Trading Arrangements
 3 Months Ended
Dec. 31, 2025
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement

10b5-1 Trading Plan Activity

Except as set forth below, during the fiscal quarter ended December 31, 2025, none of our directors or officers (as defined in Section 16 of the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(c) of Regulation S-K.

 

Name and Title of Director or Officer

Date Adopted

Type of Arrangement

Aggregate Number of Shares of Common Stock to be Sold Pursuant to Trading Arrangement

Duration

Warner Biddle, Chief Executive Officer

December 2, 2025

Rule 10b5-1 trading arrangement

434,998

December 15, 2026, or such earlier date upon which all transactions are completed or expire without execution

Westlake BioPartners Fund I, L.P. and Westlake BioPartners GP I, LLC, Affiliates of Beth Seidenberg, M.D., Director

December 4, 2025

Rule 10b5-1 distribution plan*

1,250,020

August 3, 2026, or such earlier date upon which all transactions are completed or expire without execution

*Plan provides for the distribution in-kind of shares of our common stock to partners or members of Westlake BioPartners Fund I, L.P. and Westlake BioPartners GP I, LLC and does not cover any sales of shares of our common stock.
Other Directors and Officers  
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Warner Biddle  
Trading Arrangements, by Individual  
Name Warner Biddle
Title Chief Executive Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date December 2, 2025
Expiration Date December 15, 2026
Aggregate Available 434,998
Beth Seidenberg, M.D  
Trading Arrangements, by Individual  
Name Beth Seidenberg, M.D
Title Director
Rule 10b5-1 Arrangement Adopted true
Adoption Date December 4, 2025
Expiration Date August 3, 2026
Aggregate Available 1,250,020